Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
Urologie ; 61(7): 767-769, 2022 Jul.
Article in German | MEDLINE | ID: mdl-35166861

ABSTRACT

Granulomatous and abscessing testicular inflammations are important differential diagnoses of testicular tumors. Infectious orchitis should always be considered in unclear testicular masses with negative tumor markers. We report the case of a 45-year-old man with abscessing orchitis due to early syphilis diagnosed after orchiectomy with the suspicion of a seminoma.


Subject(s)
Orchitis , Syphilis , Testicular Neoplasms , Diagnosis, Differential , Humans , Male , Middle Aged , Orchiectomy , Orchitis/diagnosis , Syphilis/diagnosis , Testicular Neoplasms/diagnosis
2.
Br J Dermatol ; 177(4): 936-944, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28278349

ABSTRACT

BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the protein, from valine to glutamic acid. BRAFV600E occurs in up to 95% of all melanoma cases and can be successfully blocked by using a combination of BRAF- and MEK inhibitors. The wider availability of next-generation sequencing is revealing more non-V600 BRAF mutations, and the clinical implications of these mutations are widely unknown. In this review, we will discuss the biology of the MAPK pathway and the different types of BRAF mutations as well as their effect on MEK activation. Current literature will be reviewed including in vitro data, case reports and case series.


Subject(s)
Melanoma/genetics , Mutation/genetics , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/genetics , Humans , MAP Kinase Kinase Kinases/genetics , MAP Kinase Signaling System/genetics , MAP Kinase Signaling System/physiology , Neoplasm Proteins/genetics , Oncogene Proteins, Fusion/genetics , ras Proteins/genetics
4.
Bone ; 88: 31-38, 2016 07.
Article in English | MEDLINE | ID: mdl-27108945

ABSTRACT

Calcification is not only physiologically present in bone but is a main pathophysiological process in vasculature, favouring cardiovascular diseases. Our aim was to investigate changes in the expression of calcification regulators during vascular calcification in bone and vasculature. Levels of gene expression of osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), osteopontin (OPN), matrix gla protein (MGP), bone sialoprotein (BSP), SMAD6, and runt-related transcription factor 2 (RUNX2) were determined in bone, aorta, and external iliac artery tissue samples of transplant donors. Histological stages of atherosclerosis (AS) in vessels are defined as "no changes", "intima thickening", or "intima calcification". Patients' bone samples were subgrouped accordingly. We demonstrate that in vessels BSP and OPN expression significantly increased during intima thickening and decreased during intima calcification, whereas the expression of regulators of calcification did not significantly change in bone during intima thickening and intima calcification. At the stage of intima thickening, MGP, OPG, and SMAD6 expression and at stage of intima calcification only MGP expression was lower in bone than in vessel. The expression of BSP and RANKL was regulated in opposite ways in bone and vessels, whereas the expression of MGP, OC, RUNX2, and OPN was regulated in a tissue-specific manner. Our study is the first direct comparison of gene expression changes during AS progression in bone and vessels. Our results indicate that changes in the expression of regulators of calcification in the vessel wall as well as in bone occur early in the calcification process, even prior to deposition of calcium/phosphate precipitation.


Subject(s)
Blood Vessels/pathology , Bone and Bones/pathology , Calcinosis/pathology , Atherosclerosis/genetics , Atherosclerosis/pathology , Bone and Bones/metabolism , Calcinosis/genetics , Female , Gene Expression Regulation , Humans , Iliac Artery/pathology , Male , Middle Aged
5.
Br J Cancer ; 108(9): 1830-7, 2013 May 14.
Article in English | MEDLINE | ID: mdl-23591196

ABSTRACT

BACKGROUND: Spinophilin, a multifunctional intracellular scaffold protein, is reduced in certain types of cancer and is regarded as a novel putative tumour suppressor protein. However, the role of spinophilin in hepatocellular carcinoma (HCC) has never been explored before. METHODS: In this study, we determined for the first time the expression pattern of spinophilin in human HCC by immunohistochemistry and quantitative reverse transcriptase-PCR analysis. In addition, we performed immunohistochemical analysis of p53, p14(ARF) and the proliferation marker Ki-67. Kaplan-Meier curves and multivariate Cox proportional models were used to study the impact on clinical outcome. Small interfering RNA (siRNA) was used to silence spinophilin and to explore the effects of reduced spinophilin expression on cellular growth. RESULTS: In our study, complete loss of spinophilin immunoreactivity was found in 44 of 104 HCCs (42.3%) and reduced levels were found in an additional 37 (35.6%) cases. After adjusting for other prognostic factors, multivariate Cox regression analysis identified low expression of spinophilin as an independent prognostic factor with respect to disease-free (hazard ratio (HR)=1.8; 95% confidence interval (CI)=1.04-3.40; P=0.043) and cancer-specific survival (HR=2.0; CI=1.1-3.8; P=0.025). Reduced spinophilin expression significantly correlated with higher Ki-67 index in HCC (P=0.014). Reducing spinophilin levels by siRNA induced a higher cellular growth rate and increased cyclin D2 expression in tumour cells (P<0.05). CONCLUSION: This is the first study of the expression pattern and distribution of spinophilin in HCC. According to our data, the loss of spinophilin is associated with higher proliferation and might be useful as a prognostic marker in patients with HCC.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/mortality , Liver Neoplasms/metabolism , Liver Neoplasms/mortality , Microfilament Proteins/metabolism , Nerve Tissue Proteins/metabolism , Tumor Suppressor Proteins/metabolism , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Cell Proliferation , Cyclin D2/biosynthesis , Disease-Free Survival , Female , Hep G2 Cells , Humans , Kaplan-Meier Estimate , Ki-67 Antigen/metabolism , Male , Microfilament Proteins/genetics , Nerve Tissue Proteins/genetics , Prognosis , Proportional Hazards Models , RNA Interference , RNA, Small Interfering , Survival Rate , Tumor Suppressor Protein p14ARF/metabolism , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/genetics
6.
Br J Cancer ; 104(10): 1641-8, 2011 May 10.
Article in English | MEDLINE | ID: mdl-21505459

ABSTRACT

BACKGROUND: The influence of human prolactin (hPRL) on the development of breast and other types of cancer is well established. Little information, however, exists on the effects of hPRL on squamous cell carcinomas of the head and neck (SCCHNs). METHODS: In this study, we evaluated prolactin receptor (PRLR) expression in SCCHN cell lines and assessed by immunohistochemistry the expression in 89 patients with SCCHNs. The PRLR expression was correlated with clinicopathological characteristics as well as clinical outcome. The effect of hPRL treatment on tumour cell growth was evaluated in vitro. RESULTS: Immunoreactivity for PRLR was observed in 85 out of 89 (95%) tumours. Multivariate COX regression analysis confirmed high levels of PRLR expression (>25% of tumour cells) to be an independent prognostic factor with respect to overall survival (HR=3.70, 95% CI: 1.14-12.01; P=0.029) and disease-free survival (P=0.017). Growth of PRLR-positive cancer cells increased in response to hPRL treatment. CONCLUSION: Our data indicate that hPRL is an important growth factor for SCCHN. Because of PRLR expression in a vast majority of tumour specimens and its negative impact on overall survival, the receptor represents a novel prognosticator and a promising drug target for patients with SCCHNs.


Subject(s)
Neoplasm Recurrence, Local/metabolism , Receptors, Prolactin/biosynthesis , Adult , Aged , Aged, 80 and over , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/pathology , Carcinoma/therapy , Carcinoma, Squamous Cell , Cell Line, Tumor , Disease-Free Survival , Female , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/therapy , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Neoplasms, Squamous Cell/genetics , Neoplasms, Squamous Cell/metabolism , Neoplasms, Squamous Cell/pathology , Neoplasms, Squamous Cell/therapy , Prognosis , Prolactin/pharmacology , Receptors, Prolactin/genetics , Squamous Cell Carcinoma of Head and Neck
7.
J Pathol ; 215(4): 431-44, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18561120

ABSTRACT

Chemokine receptors mediate migration and activation of lymphocytes through binding of their ligands. Recent studies have revealed important contributions of chemokine receptors to the development, progression, and dissemination of haematopoietic neoplasms. Because the chemokine receptor expression profile in extragastric MALT lymphoma is unknown, we performed a comprehensive study on tissue samples of parotid glands, parotid glands affected by Sjögren syndrome, extragastric MALT lymphoma, and extranodal diffuse large B-cell lymphoma (eDLBCL) originating from MALT lymphoma (transformed MALT lymphoma). By investigating the expression of 19 chemokine receptors by real-time PCR using a semi-quantitative approach and of four chemokine receptors (CCR1, CCR5, CXCR6, and XCR1) by immunohistochemistry, we show that the chemokine receptor expression profiles of extragastric MALT lymphomas differ substantially from those of extranodal DBLCL, with lower expression of CCR1, CCR8, and CXCR3, and the absence of expression of CX3CR1 and XCR1 in eDLBCL. Expression of CCR6, CCR7, CXCR3, CXCR4, and CXCR5, responsible for B-cell homing to secondary lymphoid tissue, was detected in both B-cell malignancies. Expression of CCR4 was just detected in trisomy 3-positive MALT lymphoma cases. Comparing gastric with extragastric MALT lymphomas, up-regulation of CXCR1 and CXCR2 accompanied by down-regulation of CCR8 and CX3CR1 and loss of XCR1 expression in extragastric MALT lymphomas appear to be key determinants for the site of origin of MALT lymphomagenesis. Our results support a model of stepwise progression of extragastric MALT lymphoma from a non-neoplastic event to Sjögren syndrome, to MALT lymphoma, and finally to overt eDLBCL, guided by differentially expressed B-cell homeostatic and activation-dependent chemokine receptors and their ligands.


Subject(s)
B-Lymphocytes/metabolism , Lymphoma, B-Cell, Marginal Zone/metabolism , Receptors, Chemokine/genetics , Disease Progression , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Interphase , Lymphoma, Large B-Cell, Diffuse/metabolism , Parotid Gland/metabolism , Receptors, CCR1/analysis , Receptors, CCR1/genetics , Receptors, CCR5/analysis , Receptors, CCR5/genetics , Receptors, CXCR4/genetics , Receptors, CXCR6 , Receptors, Chemokine/analysis , Receptors, G-Protein-Coupled/analysis , Receptors, G-Protein-Coupled/genetics , Receptors, Virus/analysis , Receptors, Virus/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sjogren's Syndrome/metabolism , Statistics, Nonparametric , Trisomy
8.
Pathobiology ; 74(3): 145-58, 2007.
Article in English | MEDLINE | ID: mdl-17643060

ABSTRACT

Defective protein folding is responsible for many diseases. Although these diseases seem to be quite diverse at the first glance, there is evidence for common pathogenetic principles. The basis of the pathological changes is the cell's inability to prevent protein misfolding, to revert misfolded proteins to normal or to eliminate misfolded proteins by degradation. This could result in deposition of potentially cytotoxic protein aggregates (protein aggregation diseases). Chronic degenerative diseases of the central nervous system (e.g. Alzheimer's and Parkinson's disease), the amyloidoses, but also chronic liver diseases, for example alcoholic and nonalcoholic steatohepatitis, belong to this category of disorders. This review highlights general pathogenic principles of protein aggregation diseases based on immunohistochemical and biochemical studies as well as observations in a mouse model for protein aggregation in the context of alcoholic and nonalcoholic steatohepatitis. The cellular defense mechanisms involved in protein quality control as well as the pathogenesis of protein aggregation diseases will be discussed.


Subject(s)
Molecular Chaperones/metabolism , Neurodegenerative Diseases/metabolism , Protein Folding , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloidosis/metabolism , Amyloidosis/pathology , Animals , Brain/metabolism , Brain/pathology , Chronic Disease , Disease Models, Animal , Fatty Liver, Alcoholic/metabolism , Fatty Liver, Alcoholic/pathology , Humans , Mice , Molecular Chaperones/chemistry , Neurodegenerative Diseases/pathology , Parkinson Disease/metabolism , Parkinson Disease/pathology , Protein Conformation
9.
SELECTION OF CITATIONS
SEARCH DETAIL
...